Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company focused on developing vaccines for infectious diseases, announced its participation in the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 7, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company focused on developing vaccines for infectious diseases, announced its participation in the BofA Securities 2022 Virtual Biotech SMID Cap Conference on December 7, 2022. The fireside chat will feature discussions on its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, from 9:10 – 9:35 a.m. EST. Novavax executives, including Chief Medical Officer Filip Dubovsky, will participate. A recording will be available on the company’s website for 90 days post-conference.
Details
News Market Reaction – NVAX
The recorded move for NVAX in the trading session of this news was -1.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Dec. 2, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.
Conference Details: | ||||||
Fireside Chat | ||||||
Date: | Wednesday, December 7, 2022 | |||||
Time: | 9:10 – 9:35 a.m. Eastern Standard Time (EST) | |||||
Moderator: | Alec Stranahan | |||||
Novavax participants: | Filip Dubovsky, M.D., Executive Vice President, Chief Medical Officer and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer | |||||
Conference | ||||||
Event: | Investor Meetings | |||||
Date: | Wednesday, December 7, 2022 | |||||
Recordings
A replay of the recorded fireside session will be available through the Events & presentations page of the Company's website at ir.novavax.com for 90 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. The Novavax COVID-19 vaccine has received authorization from multiple regulatory authorities globally, including the U.S. Food and Drug Administration, the European Commission, and the World Health Organization. The vaccine is currently under review by multiple regulatory agencies worldwide, including for additional indications and populations such as adolescents and as a booster. In addition to its COVID-19 vaccine, Novavax is also currently evaluating its COVID-19-Influenza Combination (CIC) vaccine candidate in a Phase 1/2 clinical trial, its quadrivalent influenza investigational vaccine candidate, and an Omicron strain-based vaccine (NVX-CoV2515) as well as a bivalent format Omicron-based / original strain-based vaccine. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on LinkedIn.
Contacts:
Investors
Erika Schultz | 240-268-2022
ir@novavax.com
Media
Ali Chartan or Giovanna Chandler | 202-709-5563
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2022-virtual-biotech-smid-cap-conference-301692230.html
SOURCE Novavax, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.